WO2001008664A1 - Compositions a liberation controlee d'acide acetylsalicylique - Google Patents

Compositions a liberation controlee d'acide acetylsalicylique Download PDF

Info

Publication number
WO2001008664A1
WO2001008664A1 PCT/EP2000/007277 EP0007277W WO0108664A1 WO 2001008664 A1 WO2001008664 A1 WO 2001008664A1 EP 0007277 W EP0007277 W EP 0007277W WO 0108664 A1 WO0108664 A1 WO 0108664A1
Authority
WO
WIPO (PCT)
Prior art keywords
controlled
acetylsalicylic acid
release
release tablets
fatty
Prior art date
Application number
PCT/EP2000/007277
Other languages
English (en)
Inventor
Mauro Valenti
Flavio Fabiani
Original Assignee
Farmaceutici Formenti S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farmaceutici Formenti S.P.A. filed Critical Farmaceutici Formenti S.P.A.
Priority to AU66983/00A priority Critical patent/AU6698300A/en
Publication of WO2001008664A1 publication Critical patent/WO2001008664A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Definitions

  • Acetylsalicylic acid has been commercially available for a long time, as an analgesic and antipyretic drug, in the form of conventional pharmaceutical compositions such as tablets, drops, suppositories and the like.
  • ASA slow- or controlled- release formulations would be desirable, in that the number of administrations could be reduced while maintaining the plasma concentrations of the drug within the therapeutical range.
  • Each tablet contains :
  • Each tablet contains :
  • Each tablet contains :
  • Each tablet contains :
  • Each tablet contains :
  • Each tablet contains:
  • a microencapsulation process is carried out with acetylsalicylic acid and ethylcellulose starting from an organic solution.
  • the resulting product was mixed with the other excipients and tabletted.
  • the determination of the in vitro release was carried out as in the above Examples .
  • Each tablet contains :

Abstract

L'invention porte sur des préparations orales solides à libération contrôlée d'acide acétylsalicylique (ASA) obtenues en soumettant le principe actif à une granulation par fusion avec un composé gras, puis en mélangeant le granulat résultant à un polymère hydrophile et à des excipients usuels.
PCT/EP2000/007277 1999-08-03 2000-07-28 Compositions a liberation controlee d'acide acetylsalicylique WO2001008664A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU66983/00A AU6698300A (en) 1999-08-03 2000-07-28 Acetylsalicylic acid controlled-release compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001738A IT1313590B1 (it) 1999-08-03 1999-08-03 Composizioni a rilascio controllato di acido acetilsalicilico.
ITMI99A001738 1999-08-03

Publications (1)

Publication Number Publication Date
WO2001008664A1 true WO2001008664A1 (fr) 2001-02-08

Family

ID=11383488

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2000/007277 WO2001008664A1 (fr) 1999-08-03 2000-07-28 Compositions a liberation controlee d'acide acetylsalicylique

Country Status (3)

Country Link
AU (1) AU6698300A (fr)
IT (1) IT1313590B1 (fr)
WO (1) WO2001008664A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384514A2 (fr) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Comprimé à double effet
WO1993018755A1 (fr) * 1992-03-25 1993-09-30 Depomed Systems, Incorporated Formes galeniques de medicament oral a liberation prolongee a base de cellulose a substitution alkyle
WO1996041617A1 (fr) * 1995-06-09 1996-12-27 Apr Applied Pharma Research S.A. Forme pharmaceutique solide a usage par voie orale

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0384514A2 (fr) * 1989-02-21 1990-08-29 Norwich Eaton Pharmaceuticals, Inc. Comprimé à double effet
WO1993018755A1 (fr) * 1992-03-25 1993-09-30 Depomed Systems, Incorporated Formes galeniques de medicament oral a liberation prolongee a base de cellulose a substitution alkyle
WO1996041617A1 (fr) * 1995-06-09 1996-12-27 Apr Applied Pharma Research S.A. Forme pharmaceutique solide a usage par voie orale

Also Published As

Publication number Publication date
IT1313590B1 (it) 2002-09-09
ITMI991738A1 (it) 2001-02-03
ITMI991738A0 (it) 1999-08-03
AU6698300A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
EP0324981B1 (fr) Formulations galéniques à libération programmée
KR100716410B1 (ko) 토피라메이트 서방성 제제 및 그의 제조방법
KR100712356B1 (ko) 서방성 제제 및 그의 제조방법
US5609884A (en) Controlled release naproxen sodium plus naproxen combination tablet
JPH11505542A (ja) 毎日一回投与するための、非晶質活性成分の一定のかつ制御された放出を行う三相型医薬製剤
WO2009034541A9 (fr) Formes galéniques à libération contrôlée à base de trimétazidine
MX2008000967A (es) Nueva composicion farmaceutica de forma de dosis de liberacion modificada que comprende inhibidor de enzima ciclooxigenasa.
IE921952A1 (en) Matrix tablet permitting the sustained release of indapamide after oral administration
KR100522239B1 (ko) 아세트아미노펜을 함유하는 제어방출성의 경구용 제제
US5624960A (en) Orally administrable drugs for the treatment of central dopamine deficiency conditions
EP1158963B1 (fr) Compositions de betahistine a liberation prolongee
AU2011288256A1 (en) Oral controlled release pharmaceutical compositions of Blonanserin
WO2001008665A1 (fr) Compositions a liberation de paracetamol controlee
WO2001008664A1 (fr) Compositions a liberation controlee d'acide acetylsalicylique
EP2095815B1 (fr) Formules pharmaceutiques contenant du clopidogrel
WO2000025750A1 (fr) Compositions de metamizole a liberation prolongee
EP0975337B1 (fr) Tablettes de flurbiprofen a liberation rapide
EP0519371B1 (fr) Formes d'administrations solides et stabilisées de compositions à base de salicylate de choline métal carboxyméthylcellulose
KR100911517B1 (ko) 신규한 서방출형 아세클로페낙 제제 조성물 및 그의제조방법
KR20180110826A (ko) 이부프로펜 및 아세트아미노펜을 포함하는 약제학적 조성물 및 이의 제조방법
KR100523242B1 (ko) 이부프로펜을 함유하는 정제 조성물
CN117427043A (zh) 一种双相控释制剂及其制备方法
JP2022027636A (ja) 安定化方法
WO2008050188A2 (fr) Compositions pharmaceutiques d'alfuzosine à libération soutenue et son processus de préparation
KR20170034707A (ko) 로플루밀라스트 함유 경구용 고형제제 및 그 제조방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP